Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
Solithromycin is a fourth generation macrolide antibiotic. This family of drugs began with erythromycin, an old standby. Over the years, other drugs in the chemical class with the same mechanism of action have been developed, notably clarithromycin and azithromycin (the Zithromax Z-pack). They act via inhibition of bacterial ribosomes. http://bit.ly/115aAII
Of particular interest with "soli," compared to older macrolides, is that it appears to act at three separate receptors on the bacterial ribosome, compared to only one or two sites for older drugs. This is believed to reduce the likelihood of bugs developing antibiotic resistance to soli, since it would require three spontaneous mutations for different receptor proteins all at the same time, to knock out all three sites of action. Big potential plus, as there are azithromycin-resistant strains in the wild.
Another big plus, macrolides appear to have anti-inflammatory activity independent of their antibacterial activity, by inhibiting neutrophil migration into sites of inflammation, particularly in the lungs. Soli has more of this activity, as measured in vitro, than previous macrolides. http://bit.ly/10Q5NGq
This is a bonus in Chronic Obstructive Pulmonary Disease, as well as in Cystic Fibrosis, both of which have a component of chronic lung inflammation as a pathological process. Studies of chronic administration of azithromycin in cystic fibrosis patients have demonstrated improved lung function over time. The downside to giving a macrolide for months or years to CF patients is the increased risk of developing community strains of resistant bacteria. See paragraph two, above.
Soli looks to be a very promising addition to the family, that is more than just a me-too drug. It actually will have some therapeutic advantages over older macrolides that are now generic. The current Phase III trial in community acquired pneumonia is due to finish in April 2014. All trial data to date have been very encouraging.
There is also a phase II trial underway using a one-dose oral treatment with Soli for gonorrhea. Another excellent market, as community strains have developed resistance to many other antibiotics. A single shot in the butt of penicillin is no longer the best choice there.
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) [View article]
The anti-inflammatory effect of solithromycin in COPD has already been presented in a poster available on the company's website.
This compound will have even better immunomodulatory activity than currently available macrolides, which will be important in the treatment of community-acquired pneumonia in COPD and Cystic Fibrosis patients.
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) [View article]
The paper of the full study is available free online:
"Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia" David Oldacha, Kay Clarka, Jennifer Schranza*, Anita Dasb, J Carl Crafta, Drusilla Scotta, Brian D. Jamiesona and Prabhavathi Fernandesa
Antimicrob. Agents Chemother. June 2013 vol. 57 no. 6 2526-2534
>> Last year Robert Couch of Baylor College tested four experimental SARS vaccines in mice. All the vaccinated animals resisted infection, yet exposure to the SARS virus led to a severe lung inflammation similar to that seen with the RSV vaccine. The same thing, he reported, has been seen with many other experimental SARS vaccines.
The problem seems to be that rather than aiding the destruction of the invading virus, the antibodies switch sides. Malik Peiris of the University of Hong Kong found that antibodies to a vaccine made from the main surface protein of SARS allow the virus to enter immune cells, where they can trigger a destructive immune attack on the lung. <<
Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
Shuttlecocks to cost more due to H7N9 By Ou Hailin (China Daily) 11:18, May 17, 2013 Feather market in 'chaos' as concerns over bird flu affect supply, production
Bad news for badminton fans: The price of shuttlecocks will rise in coming months as the supply of duck feathers needed to make them dwindles because of the H7N9 bird flu outbreak.
"We're planning an increase of 4 or 5 yuan (65 to 81 US cents) for each pack of 12 shuttlecocks in July, if bird flu has not been brought under control by then," said Liu Zhisong, a technical manager at Bo'er Shuttlecock Factory, one of the largest shuttlecock manufacturers in Anhui province.
.......
"The feather market is in total chaos," said Li Min, whose business focuses on supplying processed feathers to shuttlecock producers. "In just 20 days after the outbreak of H7N9, the price of natural duck feathers increased by about 40 percent. And even with the high price, it's hard to get them right now."
The inexorable laws of supply and demand threaten the noble game... "Usually, most shuttlecock producers would keep a two-month storage of feathers," Jin said. "But if H7N9 continues and governments' restrictions on trade in the live poultry market do not end, not only the price will shoot up, the shuttlecock industry itself will be in peril."
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
Steve Bay,
With all due respect and in fairness, it is not JP's job to manage our expectations or assuage our anxiety about investing in a high risk R&D penny stock.
He has provided a wealth of technical and legal expertise, as well as deep insight about the corporate philosophy as a former insider. For that I am grateful, as it has helped me to see the remarkable potential of this company. But I would not want him to change his consistent stance of professional boundary lines with respect to a former client and employer to become simply a cheerleader to entice investors.
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
;-)
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
NASA or DOD league?
Were the cooling plates made of unobtainium?
Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
http://bit.ly/115aAII
Of particular interest with "soli," compared to older macrolides, is that it appears to act at three separate receptors on the bacterial ribosome, compared to only one or two sites for older drugs. This is believed to reduce the likelihood of bugs developing antibiotic resistance to soli, since it would require three spontaneous mutations for different receptor proteins all at the same time, to knock out all three sites of action. Big potential plus, as there are azithromycin-resistant strains in the wild.
Another big plus, macrolides appear to have anti-inflammatory activity independent of their antibacterial activity, by inhibiting neutrophil migration into sites of inflammation, particularly in the lungs. Soli has more of this activity, as measured in vitro, than previous macrolides. http://bit.ly/10Q5NGq
This is a bonus in Chronic Obstructive Pulmonary Disease, as well as in Cystic Fibrosis, both of which have a component of chronic lung inflammation as a pathological process. Studies of chronic administration of azithromycin in cystic fibrosis patients have demonstrated improved lung function over time. The downside to giving a macrolide for months or years to CF patients is the increased risk of developing community strains of resistant bacteria. See paragraph two, above.
Soli looks to be a very promising addition to the family, that is more than just a me-too drug. It actually will have some therapeutic advantages over older macrolides that are now generic. The current Phase III trial in community acquired pneumonia is due to finish in April 2014. All trial data to date have been very encouraging.
There is also a phase II trial underway using a one-dose oral treatment with Soli for gonorrhea. Another excellent market, as community strains have developed resistance to many other antibiotics. A single shot in the butt of penicillin is no longer the best choice there.
Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
http://bit.ly/14ohVlw
Company website about solithromycin: http://bit.ly/10IRAOt
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) [View article]
http://bit.ly/10Q5NGq
This compound will have even better immunomodulatory activity than currently available macrolides, which will be important in the treatment of community-acquired pneumonia in COPD and Cystic Fibrosis patients.
http://1.usa.gov/11510pa
http://1.usa.gov/10Q5NWE
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) [View article]
http://bit.ly/12GN1En
"Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia"
David Oldacha, Kay Clarka, Jennifer Schranza*, Anita Dasb, J Carl Crafta, Drusilla Scotta, Brian D. Jamiesona and Prabhavathi Fernandesa
Antimicrob. Agents Chemother. June 2013 vol. 57 no. 6 2526-2534
Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
http://bit.ly/12EzkFU
>>
Last year Robert Couch of Baylor College tested four experimental SARS vaccines in mice. All the vaccinated animals resisted infection, yet exposure to the SARS virus led to a severe lung inflammation similar to that seen with the RSV vaccine. The same thing, he reported, has been seen with many other experimental SARS vaccines.
The problem seems to be that rather than aiding the destruction of the invading virus, the antibodies switch sides. Malik Peiris of the University of Hong Kong found that antibodies to a vaccine made from the main surface protein of SARS allow the virus to enter immune cells, where they can trigger a destructive immune attack on the lung.
<<
Swine Flu AND Medical News Concentrator April 25, 2013 To ??? [View instapost]
By Ou Hailin (China Daily)
11:18, May 17, 2013
Feather market in 'chaos' as concerns over bird flu affect supply, production
Bad news for badminton fans: The price of shuttlecocks will rise in coming months as the supply of duck feathers needed to make them dwindles because of the H7N9 bird flu outbreak.
"We're planning an increase of 4 or 5 yuan (65 to 81 US cents) for each pack of 12 shuttlecocks in July, if bird flu has not been brought under control by then," said Liu Zhisong, a technical manager at Bo'er Shuttlecock Factory, one of the largest shuttlecock manufacturers in Anhui province.
.......
"The feather market is in total chaos," said Li Min, whose business focuses on supplying processed feathers to shuttlecock producers. "In just 20 days after the outbreak of H7N9, the price of natural duck feathers increased by about 40 percent. And even with the high price, it's hard to get them right now."
http://bit.ly/Z5tuPA
The inexorable laws of supply and demand threaten the noble game...
"Usually, most shuttlecock producers would keep a two-month storage of feathers," Jin said. "But if H7N9 continues and governments' restrictions on trade in the live poultry market do not end, not only the price will shoot up, the shuttlecock industry itself will be in peril."
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
http://on.jci.com/18QjY4M
They have manufacturing facilities all over the southeast:
http://on.jci.com/14xicSK
Axion Power Concentrator 236: May 15: Axion Power Releases Quarterly Report For The First Quarter 2013 [View instapost]
Axion Power Concentrator 237: May 16: Axion Power Reports First Quarter Results For 2013 [View instapost]
With all due respect and in fairness, it is not JP's job to manage our expectations or assuage our anxiety about investing in a high risk R&D penny stock.
He has provided a wealth of technical and legal expertise, as well as deep insight about the corporate philosophy as a former insider. For that I am grateful, as it has helped me to see the remarkable potential of this company. But I would not want him to change his consistent stance of professional boundary lines with respect to a former client and employer to become simply a cheerleader to entice investors.
Axion Power Concentrator 236: May 15: Axion Power Releases Quarterly Report For The First Quarter 2013 [View instapost]
Rick, yer gonna give me nightmares if I can stop laughing.
Axion Power Concentrator 236: May 15: Axion Power Releases Quarterly Report For The First Quarter 2013 [View instapost]
Here is a clue:
http://bit.ly/18OggZq
Not our greatest hope.
Axion Power Concentrator 236: May 15: Axion Power Releases Quarterly Report For The First Quarter 2013 [View instapost]
Would they do a phased roll-out of PbC ISS systems, starting in the States and then extending to Europe?
that could give Axion time to grow and extend to other strategic partners world-wide in an orderly fashion.